Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis

Toshihiko Kawamori, Karam El-Bayoumy, Ben Yi Ji, Jose G. Rosa Rodriguez, Chinthalapally V. Rao, Bandaru S. Reddy

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Observational, clinical and experimental studies have suggested that dietary supplementation with selenium can inhibit the development of colon cancer. Since toxicity and chemopreventive efficacy of selenium compounds depend to a large extent, on the form of selenium the development of efficacious organoselenium compounds with low toxicity is being pursued in our laboratory. We have assessed the chemopreventive properties of a newly synthesized organoselenium compound, benzyl selenocyanate glutathione conjugate (BSeSG), and of benzyl selenocyanate (BSC), as a positive control, using azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) as a measure of efficacy. Fiveweek-old male F344 rats were fed the control diet (modified AIN-76A) or experimental diets containing 10 or 20 ppm BSeSG (1.7 and 3.4 ppm as Se, respectively), or 10 ppm BSC (4.1 ppm as Se). One week later, all animals except those in vehicle (normal saline)-treated groups were s.c. injected with AOM (15 mg/kg of body weight, once weekly for 2 weeks). All animals were sacrificed 7 weeks after the last AOM injection, and the ACF, levels of prostaglandin E2 (PGE2), cyclooxygenase protein expression (COX-1 and -2), and glutathione S-transferase type μ (GST-μ) were determined in the colon. As expected, dietary administration of BSC suppressed ACF development by about 37%. In rats administered 10 or 20 ppm BSeSG, the frequencies of AOM-induced colonic ACF were significantly decreased compared to those of rats given AOM and control diet by about 41% (P<0.01) and 61% (P<0.001), respectively. Administration of BSeSG inhibited PGE2 production (81-88% inhibition) via COX-2 synthesis in the colonic mucosa (18-60% inhibition). Also, BSeSG increased GST-μ protein activity in colonic mucosa (30-32% increase). These data suggest that a newly synthesized organoselenium compound, BSeSG might be a promising chemopreventive agent against colon carcinogenesis.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalInternational journal of oncology
Volume13
Issue number1
StatePublished - Jul 1 1998

Fingerprint

Azoxymethane
Aberrant Crypt Foci
Organoselenium Compounds
Colon
Carcinogenesis
Selenium
Diet
Dinoprostone
Mucous Membrane
Selenium Compounds
Inbred F344 Rats
Prostaglandin-Endoperoxide Synthases
Dietary Supplements
Glutathione Transferase
Colonic Neoplasms
Proteins
Body Weight
N-(2-(carboxymethyl)amino-2-oxo-1-((((phenylmethyl)seleno)thio)methyl)ethyl)glutamine
Injections
benzyl selenocyanate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kawamori, Toshihiko ; El-Bayoumy, Karam ; Ji, Ben Yi ; Rosa Rodriguez, Jose G. ; Rao, Chinthalapally V. ; Reddy, Bandaru S. / Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis. In: International journal of oncology. 1998 ; Vol. 13, No. 1. pp. 29-34.
@article{7ae16b2360144081b4a61bda3d6b5b78,
title = "Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis",
abstract = "Observational, clinical and experimental studies have suggested that dietary supplementation with selenium can inhibit the development of colon cancer. Since toxicity and chemopreventive efficacy of selenium compounds depend to a large extent, on the form of selenium the development of efficacious organoselenium compounds with low toxicity is being pursued in our laboratory. We have assessed the chemopreventive properties of a newly synthesized organoselenium compound, benzyl selenocyanate glutathione conjugate (BSeSG), and of benzyl selenocyanate (BSC), as a positive control, using azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) as a measure of efficacy. Fiveweek-old male F344 rats were fed the control diet (modified AIN-76A) or experimental diets containing 10 or 20 ppm BSeSG (1.7 and 3.4 ppm as Se, respectively), or 10 ppm BSC (4.1 ppm as Se). One week later, all animals except those in vehicle (normal saline)-treated groups were s.c. injected with AOM (15 mg/kg of body weight, once weekly for 2 weeks). All animals were sacrificed 7 weeks after the last AOM injection, and the ACF, levels of prostaglandin E2 (PGE2), cyclooxygenase protein expression (COX-1 and -2), and glutathione S-transferase type μ (GST-μ) were determined in the colon. As expected, dietary administration of BSC suppressed ACF development by about 37{\%}. In rats administered 10 or 20 ppm BSeSG, the frequencies of AOM-induced colonic ACF were significantly decreased compared to those of rats given AOM and control diet by about 41{\%} (P<0.01) and 61{\%} (P<0.001), respectively. Administration of BSeSG inhibited PGE2 production (81-88{\%} inhibition) via COX-2 synthesis in the colonic mucosa (18-60{\%} inhibition). Also, BSeSG increased GST-μ protein activity in colonic mucosa (30-32{\%} increase). These data suggest that a newly synthesized organoselenium compound, BSeSG might be a promising chemopreventive agent against colon carcinogenesis.",
author = "Toshihiko Kawamori and Karam El-Bayoumy and Ji, {Ben Yi} and {Rosa Rodriguez}, {Jose G.} and Rao, {Chinthalapally V.} and Reddy, {Bandaru S.}",
year = "1998",
month = "7",
day = "1",
language = "English (US)",
volume = "13",
pages = "29--34",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis. / Kawamori, Toshihiko; El-Bayoumy, Karam; Ji, Ben Yi; Rosa Rodriguez, Jose G.; Rao, Chinthalapally V.; Reddy, Bandaru S.

In: International journal of oncology, Vol. 13, No. 1, 01.07.1998, p. 29-34.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis

AU - Kawamori, Toshihiko

AU - El-Bayoumy, Karam

AU - Ji, Ben Yi

AU - Rosa Rodriguez, Jose G.

AU - Rao, Chinthalapally V.

AU - Reddy, Bandaru S.

PY - 1998/7/1

Y1 - 1998/7/1

N2 - Observational, clinical and experimental studies have suggested that dietary supplementation with selenium can inhibit the development of colon cancer. Since toxicity and chemopreventive efficacy of selenium compounds depend to a large extent, on the form of selenium the development of efficacious organoselenium compounds with low toxicity is being pursued in our laboratory. We have assessed the chemopreventive properties of a newly synthesized organoselenium compound, benzyl selenocyanate glutathione conjugate (BSeSG), and of benzyl selenocyanate (BSC), as a positive control, using azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) as a measure of efficacy. Fiveweek-old male F344 rats were fed the control diet (modified AIN-76A) or experimental diets containing 10 or 20 ppm BSeSG (1.7 and 3.4 ppm as Se, respectively), or 10 ppm BSC (4.1 ppm as Se). One week later, all animals except those in vehicle (normal saline)-treated groups were s.c. injected with AOM (15 mg/kg of body weight, once weekly for 2 weeks). All animals were sacrificed 7 weeks after the last AOM injection, and the ACF, levels of prostaglandin E2 (PGE2), cyclooxygenase protein expression (COX-1 and -2), and glutathione S-transferase type μ (GST-μ) were determined in the colon. As expected, dietary administration of BSC suppressed ACF development by about 37%. In rats administered 10 or 20 ppm BSeSG, the frequencies of AOM-induced colonic ACF were significantly decreased compared to those of rats given AOM and control diet by about 41% (P<0.01) and 61% (P<0.001), respectively. Administration of BSeSG inhibited PGE2 production (81-88% inhibition) via COX-2 synthesis in the colonic mucosa (18-60% inhibition). Also, BSeSG increased GST-μ protein activity in colonic mucosa (30-32% increase). These data suggest that a newly synthesized organoselenium compound, BSeSG might be a promising chemopreventive agent against colon carcinogenesis.

AB - Observational, clinical and experimental studies have suggested that dietary supplementation with selenium can inhibit the development of colon cancer. Since toxicity and chemopreventive efficacy of selenium compounds depend to a large extent, on the form of selenium the development of efficacious organoselenium compounds with low toxicity is being pursued in our laboratory. We have assessed the chemopreventive properties of a newly synthesized organoselenium compound, benzyl selenocyanate glutathione conjugate (BSeSG), and of benzyl selenocyanate (BSC), as a positive control, using azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) as a measure of efficacy. Fiveweek-old male F344 rats were fed the control diet (modified AIN-76A) or experimental diets containing 10 or 20 ppm BSeSG (1.7 and 3.4 ppm as Se, respectively), or 10 ppm BSC (4.1 ppm as Se). One week later, all animals except those in vehicle (normal saline)-treated groups were s.c. injected with AOM (15 mg/kg of body weight, once weekly for 2 weeks). All animals were sacrificed 7 weeks after the last AOM injection, and the ACF, levels of prostaglandin E2 (PGE2), cyclooxygenase protein expression (COX-1 and -2), and glutathione S-transferase type μ (GST-μ) were determined in the colon. As expected, dietary administration of BSC suppressed ACF development by about 37%. In rats administered 10 or 20 ppm BSeSG, the frequencies of AOM-induced colonic ACF were significantly decreased compared to those of rats given AOM and control diet by about 41% (P<0.01) and 61% (P<0.001), respectively. Administration of BSeSG inhibited PGE2 production (81-88% inhibition) via COX-2 synthesis in the colonic mucosa (18-60% inhibition). Also, BSeSG increased GST-μ protein activity in colonic mucosa (30-32% increase). These data suggest that a newly synthesized organoselenium compound, BSeSG might be a promising chemopreventive agent against colon carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0031835148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031835148&partnerID=8YFLogxK

M3 - Article

C2 - 9625800

AN - SCOPUS:0031835148

VL - 13

SP - 29

EP - 34

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -